1. Home
  2. PMI vs INTS Comparison

PMI vs INTS Comparison

Compare PMI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PMI

Picard Medical Inc.

HOLD

Current Price

$0.13

Market Cap

14.1M

Sector

N/A

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

N/A

Current Price

$4.49

Market Cap

12.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PMI
INTS
Founded
1981
2012
Country
United States
United States
Employees
75
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.1M
12.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PMI
INTS
Price
$0.13
$4.49
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$38.00
AVG Volume (30 Days)
13.1M
22.8K
Earning Date
06-18-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.19
52 Week High
$13.68
$8.06

Technical Indicators

Market Signals
Indicator
PMI
INTS
Relative Strength Index (RSI) 17.57 30.09
Support Level N/A $0.31
Resistance Level $0.27 $8.06
Average True Range (ATR) 0.03 0.20
MACD 0.02 -0.02
Stochastic Oscillator 16.11 8.63

Price Performance

Historical Comparison
PMI
INTS

About PMI Picard Medical Inc.

Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: